See the DrugPatentWatch profile for Cimzia
Cimzia, a medication used to treat inflammatory conditions, was launched by UCB Pharma [1]. It is a tumor necrosis factor (TNF) inhibitor [2].
What conditions does Cimzia treat?
Cimzia is approved for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy [2]. It is also indicated for the treatment of active psoriatic arthritis in adult patients [2]. Additionally, Cimzia is used to reduce signs and symptoms of active ankylosing spondylitis in adult patients [2]. For patients with Crohn's disease, Cimzia is prescribed to reduce signs and symptoms and to induce and maintain clinical remission [2]. It is also used to treat active rheumatoid arthritis in adult patients [2].
When did Cimzia become available?
The first approval for Cimzia in the United States was in October 2008 for Crohn's disease [3]. Subsequent approvals expanded its use to rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with approvals in 2009 and 2011 [3]. Cimzia received its initial FDA approval for plaque psoriasis in 2017 [2].
How does Cimzia work?
Cimzia works by targeting tumor necrosis factor-alpha (TNF-alpha), a protein that plays a key role in inflammation [4]. By blocking TNF-alpha, Cimzia can help reduce the inflammation associated with conditions like rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis [4].
What are the side effects of Cimzia?
Common side effects of Cimzia can include upper respiratory tract infections, rash, and urinary tract infections [2]. Serious side effects may involve an increased risk of serious infections, malignancy, and allergic reactions [2]. Patients are advised to report any new or worsening symptoms to their doctor [2].
What is the patent status of Cimzia?
Patent information for drugs like Cimzia can be complex and is tracked by resources such as DrugPatentWatch.com [1]. Details regarding patent expiry dates and any associated litigation are crucial for understanding market exclusivity and the potential for generic or biosimilar competition.
How is Cimzia administered?
Cimzia is administered as a subcutaneous injection [2]. It is typically given by a healthcare professional, but patients may be trained to administer it themselves at home [2].
Who is UCB Pharma, the maker of Cimzia?
UCB Pharma is a global biopharmaceutical company focused on neurology and immunology [1]. They develop and market medicines to help people living with severe diseases of the brain and the immune system [1].